ERBB2 and breast carcinoma: It deserves notice that all AKT1 p.E17K mutations came from estrogen receptor (ER)-positive/human epidermal growth factor receptor II (HER2)-negative breast cancers, and most were diagnosed with late-stage disease (Groups 3-1 and 3-2, n = 7).